AR036700A1 - Forma de dosificacion oral solida de simeticona - Google Patents
Forma de dosificacion oral solida de simeticonaInfo
- Publication number
- AR036700A1 AR036700A1 ARP020103669A ARP020103669A AR036700A1 AR 036700 A1 AR036700 A1 AR 036700A1 AR P020103669 A ARP020103669 A AR P020103669A AR P020103669 A ARP020103669 A AR P020103669A AR 036700 A1 AR036700 A1 AR 036700A1
- Authority
- AR
- Argentina
- Prior art keywords
- dosage form
- simethicone
- adsorbent
- simeticone
- oral dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/966,441 US7101573B2 (en) | 2001-09-28 | 2001-09-28 | Simethicone solid oral dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036700A1 true AR036700A1 (es) | 2004-09-29 |
Family
ID=25511414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103669A AR036700A1 (es) | 2001-09-28 | 2002-09-27 | Forma de dosificacion oral solida de simeticona |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7101573B2 (enExample) |
| EP (1) | EP1297825B1 (enExample) |
| AR (1) | AR036700A1 (enExample) |
| AT (1) | ATE296619T1 (enExample) |
| AU (1) | AU2002301259C1 (enExample) |
| BR (1) | BR0204001A (enExample) |
| CA (1) | CA2405190C (enExample) |
| CO (1) | CO5390073A1 (enExample) |
| DE (1) | DE60204403T2 (enExample) |
| DK (1) | DK1297825T3 (enExample) |
| ES (1) | ES2243664T3 (enExample) |
| HU (1) | HUP0203176A2 (enExample) |
| MX (1) | MXPA02009570A (enExample) |
| NZ (1) | NZ521657A (enExample) |
| PL (1) | PL204141B1 (enExample) |
| PT (1) | PT1297825E (enExample) |
| RU (1) | RU2362569C2 (enExample) |
| ZA (1) | ZA200207755B (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US6955821B2 (en) | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
| US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| US8012504B2 (en) * | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| US7838032B2 (en) * | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
| US20070053895A1 (en) | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
| US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
| AU2002219964A1 (en) * | 2001-11-29 | 2003-06-17 | Penwest Pharmaceutical Company | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
| US7179488B2 (en) | 2001-11-29 | 2007-02-20 | Bob Sherwood | Process for co-spray drying liquid herbal extracts with dry silicified MCC |
| SE0200895D0 (sv) * | 2002-03-22 | 2002-03-22 | Astrazeneca Ab | New pharmaceutical composition |
| US7341742B2 (en) * | 2002-09-30 | 2008-03-11 | L. Perrigo Company | Simethicone containing tablet composition and method |
| EP1563837A1 (en) * | 2004-02-03 | 2005-08-17 | Ferrer Internacional, S.A. | Hypocholesterolemic compositions comprising a statin and an antiflatulent agent |
| CA2559239C (en) * | 2004-04-13 | 2021-04-06 | Boehringer Ingelheim International Gmbh | Use of simethicone and sodium picosulphate in constipated patients suffering from bloated feeling and gas discomfort during the night |
| US20080255104A1 (en) * | 2004-05-04 | 2008-10-16 | Equitech Corporation | Nsaid Compositions |
| US20060024384A1 (en) * | 2004-07-29 | 2006-02-02 | Giordano John A | Compositions and methods for nutrition supplementation |
| US20060024409A1 (en) * | 2004-07-29 | 2006-02-02 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
| US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
| KR20140065482A (ko) * | 2005-03-24 | 2014-05-29 | 다이이찌 산쿄 가부시키가이샤 | 의약용 조성물 |
| BRPI0615607A2 (pt) * | 2005-08-30 | 2011-05-24 | Lek Pharmaceuticals | composição farmacêutica compreendendo perindopril ou seus sais |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| KR101252635B1 (ko) * | 2006-04-20 | 2013-04-10 | (주)아모레퍼시픽 | 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제 |
| US20080015260A1 (en) * | 2006-07-13 | 2008-01-17 | Kiel Laboratories, Inc. | Pharmaceutical compositions having improved stability and methods for preparation and use |
| US20080038410A1 (en) * | 2006-08-18 | 2008-02-14 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
| AU2007317561A1 (en) | 2006-10-27 | 2008-05-15 | The Curators Of The University Of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
| WO2008056200A1 (en) * | 2006-11-10 | 2008-05-15 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of simethicone |
| WO2008064192A2 (en) | 2006-11-21 | 2008-05-29 | Mcneil-Ppc, Inc. | Modified release analgesic suspensions |
| US9833510B2 (en) * | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
| US20090004248A1 (en) * | 2007-06-29 | 2009-01-01 | Frank Bunick | Dual portion dosage lozenge form |
| CN101980700A (zh) | 2008-02-20 | 2011-02-23 | 密苏里大学董事会 | 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法 |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| ES2732453T3 (es) | 2008-07-01 | 2019-11-22 | Curemark Llc | Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental |
| US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| JP2012514604A (ja) | 2009-01-06 | 2012-06-28 | キュレロン リミテッド ライアビリティ カンパニー | 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法 |
| CA3050530A1 (en) | 2009-01-06 | 2010-07-15 | Galenagen, Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
| US20100247586A1 (en) * | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| JP5410819B2 (ja) * | 2009-04-09 | 2014-02-05 | ライオン株式会社 | 木クレオソート含有固形製剤 |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| MX362974B (es) | 2011-04-21 | 2019-02-28 | Curemark Llc | Compuestos para el tratamiento de alteraciones neuropsiquiatricas. |
| EP2717860A4 (en) * | 2011-06-08 | 2014-11-05 | Sti Pharma Llc | FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION |
| JP6280501B2 (ja) | 2011-09-08 | 2018-02-14 | メレオ バイオファーマ ２ リミテッド | 性腺機能低下症および関連疾患の処置ためのアロマターゼ阻害剤の使用 |
| IN2014DN03373A (enExample) * | 2011-10-27 | 2015-06-05 | Borody Thomas J | |
| ITMI20112221A1 (it) * | 2011-12-05 | 2013-06-06 | Altergon Sa | Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio |
| CA2858821A1 (en) | 2011-12-14 | 2013-06-27 | Disphar International B.V. | Simethicone formulation |
| RU2491941C1 (ru) * | 2011-12-27 | 2013-09-10 | Вадим Алексеевич Козловский | Композиционный энтеросорбент |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| GB201506755D0 (en) | 2015-04-21 | 2015-06-03 | Reckitt Benckiser Llc | Novel pharmaceutical formulation |
| MA41620A (fr) | 2015-05-14 | 2018-01-09 | Abdi Ibrahim Ilac Sanayi Ve Ticaret A S | Composition pharmaceutique comprenant de la siméthicone et de l'otilonium |
| JP6724537B2 (ja) * | 2015-05-26 | 2020-07-15 | 大正製薬株式会社 | 固形製剤 |
| US10166185B2 (en) * | 2015-06-09 | 2019-01-01 | J. Rettenmaier & Söhne Gmbh + Co Kg | Excipient and oral solid dosage forms for oily drugs |
| WO2016201119A1 (en) * | 2015-06-09 | 2016-12-15 | J. Rettenmaier & Söhne Gmbh + Co Kg | Excipient and oral solid dosage forms for oily drugs |
| EP3294269A1 (en) | 2015-06-12 | 2018-03-21 | Santa Farma Ilaç Sanayi A.S. | Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics |
| US11278506B2 (en) | 2015-10-09 | 2022-03-22 | Rb Health (Us) Llc | Pharmaceutical formulation |
| MX385008B (es) * | 2016-12-14 | 2025-03-14 | Rhein Siegfried Sa De Cv | Composicion mejorada de lansoprazol y simeticona y procesos para prepararla. |
| AU2018250823A1 (en) | 2017-04-10 | 2019-10-17 | Curemark, Llc | Compositions for treating addiction |
| EP3687502B1 (en) | 2017-09-29 | 2023-06-07 | Johnson & Johnson Consumer Inc. | Solid simethicone particles and dosage form thereof |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| FR3117780B1 (fr) * | 2020-12-22 | 2024-04-05 | Oreal | Composition anhydre sous forme de poudre compacte comprenant un sel de magnesium et de la cellulose microcristalline |
| CN116159032A (zh) * | 2023-03-31 | 2023-05-26 | 成都恒瑞制药有限公司 | 盐酸西替利嗪片及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56169622A (en) * | 1980-06-03 | 1981-12-26 | Kissei Pharmaceut Co Ltd | Method of making solid preparation from oily substance |
| US4744987A (en) * | 1985-03-08 | 1988-05-17 | Fmc Corporation | Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation |
| US4851226A (en) | 1987-11-16 | 1989-07-25 | Mcneil Consumer Products Company | Chewable medicament tablet containing means for taste masking |
| US4906478A (en) | 1988-12-12 | 1990-03-06 | Valentine Enterprises, Inc. | Simethicone/calcium silicate composition |
| US5073384A (en) | 1989-10-19 | 1991-12-17 | Valentine Enterprises, Inc. | Maltodextrin/defoaming composition combinate |
| US5275822A (en) | 1989-10-19 | 1994-01-04 | Valentine Enterprises, Inc. | Defoaming composition |
| NZ235876A (en) | 1989-11-01 | 1992-06-25 | Mcneil Ppc Inc | Pharmaceutical compositions containing effective amount of antidiarrheal composition and antiflatulent effective amount of simethicone |
| US5075114A (en) | 1990-05-23 | 1991-12-24 | Mcneil-Ppc, Inc. | Taste masking and sustained release coatings for pharmaceuticals |
| CA2068402C (en) | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
| JP3177707B2 (ja) | 1991-10-08 | 2001-06-18 | 堀井薬品工業株式会社 | 消化管内ガス除去剤 |
| US5599557A (en) * | 1992-04-30 | 1997-02-04 | Schering Corporation | Stable hydrated cephalosporin dry powder for oral suspension formulation |
| GR1002332B (el) * | 1992-05-21 | 1996-05-16 | Mcneil-Ppc Inc. | Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη. |
| CA2110313C (en) * | 1992-12-01 | 2004-10-26 | Edward John Roche | Pharmaceutical compositions containing a guanidinothiazole compound and antacids |
| FR2705966B1 (fr) | 1993-06-04 | 1995-08-25 | Dow Corning Sa | Compositions antimousse utiles notamment pour le traitement de troubles gastriques. |
| AU8084594A (en) * | 1993-10-28 | 1995-05-22 | Procter & Gamble Company, The | Fast dissolving dosage forms containing magnesium aluminum silicate and multiple active ingredients |
| DE69426863T2 (de) | 1993-12-15 | 2001-09-27 | National Starch And Chemical Investment Holding Corp., Wilmington | Verwendung von Öl adsorbierenden natürlichen Polymeren in kosmetischen und pharmazeutischen Anwendungen |
| US5585115A (en) * | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| IL116674A (en) * | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| US6106865A (en) * | 1995-01-09 | 2000-08-22 | Edward Mendell Co., Inc. | Pharmaceutical excipient having improved compressibility |
| US6103260A (en) * | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
| US6190696B1 (en) * | 1998-06-08 | 2001-02-20 | Pieter J. Groenewoud | Stabilized thyroxine medications |
| US6126967A (en) | 1998-09-03 | 2000-10-03 | Ascent Pediatrics | Extended release acetaminophen particles |
| US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
-
2001
- 2001-09-28 US US09/966,441 patent/US7101573B2/en not_active Expired - Lifetime
-
2002
- 2002-09-25 CA CA2405190A patent/CA2405190C/en not_active Expired - Fee Related
- 2002-09-26 ZA ZA200207755A patent/ZA200207755B/xx unknown
- 2002-09-26 HU HU0203176A patent/HUP0203176A2/hu unknown
- 2002-09-27 PL PL356358A patent/PL204141B1/pl unknown
- 2002-09-27 MX MXPA02009570A patent/MXPA02009570A/es active IP Right Grant
- 2002-09-27 PT PT02256741T patent/PT1297825E/pt unknown
- 2002-09-27 AR ARP020103669A patent/AR036700A1/es not_active Application Discontinuation
- 2002-09-27 RU RU2002125821/15A patent/RU2362569C2/ru not_active IP Right Cessation
- 2002-09-27 AU AU2002301259A patent/AU2002301259C1/en not_active Ceased
- 2002-09-27 DE DE60204403T patent/DE60204403T2/de not_active Expired - Lifetime
- 2002-09-27 ES ES02256741T patent/ES2243664T3/es not_active Expired - Lifetime
- 2002-09-27 DK DK02256741T patent/DK1297825T3/da active
- 2002-09-27 EP EP02256741A patent/EP1297825B1/en not_active Expired - Lifetime
- 2002-09-27 AT AT02256741T patent/ATE296619T1/de not_active IP Right Cessation
- 2002-09-27 CO CO02087102A patent/CO5390073A1/es not_active Application Discontinuation
- 2002-09-27 NZ NZ521657A patent/NZ521657A/en unknown
- 2002-09-30 BR BR0204001-8A patent/BR0204001A/pt not_active Application Discontinuation
-
2006
- 2006-07-28 US US11/460,741 patent/US7691409B2/en not_active Expired - Lifetime
-
2010
- 2010-02-03 US US12/699,129 patent/US20100135982A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20070196468A1 (en) | 2007-08-23 |
| DE60204403D1 (de) | 2005-07-07 |
| CA2405190C (en) | 2010-11-09 |
| RU2362569C2 (ru) | 2009-07-27 |
| US20100135982A1 (en) | 2010-06-03 |
| MXPA02009570A (es) | 2004-07-30 |
| PL356358A1 (en) | 2003-04-07 |
| EP1297825A1 (en) | 2003-04-02 |
| US7691409B2 (en) | 2010-04-06 |
| HU0203176D0 (enExample) | 2002-11-28 |
| ES2243664T3 (es) | 2005-12-01 |
| US7101573B2 (en) | 2006-09-05 |
| DK1297825T3 (da) | 2005-09-26 |
| PT1297825E (pt) | 2005-08-31 |
| ATE296619T1 (de) | 2005-06-15 |
| ZA200207755B (en) | 2004-03-26 |
| CA2405190A1 (en) | 2003-03-28 |
| PL204141B1 (pl) | 2009-12-31 |
| NZ521657A (en) | 2004-05-28 |
| HUP0203176A2 (hu) | 2004-07-28 |
| BR0204001A (pt) | 2003-09-16 |
| AU2002301259B2 (en) | 2009-01-22 |
| CO5390073A1 (es) | 2004-04-30 |
| RU2002125821A (ru) | 2004-03-27 |
| DE60204403T2 (de) | 2006-05-04 |
| US20030091624A1 (en) | 2003-05-15 |
| AU2002301259C1 (en) | 2009-07-23 |
| EP1297825B1 (en) | 2005-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5390073A1 (es) | Forma de dosificacion oral solida de simeticona | |
| MXPA05007643A (es) | Metodo para producir una forma farmaceutica oral con desintegracion inmediata y liberacion de ingrediente activo. | |
| AR059324A2 (es) | Una forma solida de dosificacion oral | |
| BR0311867A (pt) | Forma de ministração adesiva a mucosa em forma de pelìcula e uso de um extrato ou de um óleo de cannabis para a produção de uma forma de ministração adesiva a mucosa em forma de pelìcula | |
| JP2003520232A5 (enExample) | ||
| ES2182357T3 (es) | Nueva utilizacion de budesonide y formoterol. | |
| AR013227A1 (es) | COMPOSICIoN GRANULAR DE SIMETICONA QUE FLUYE LIBREMENTE, FORMA DE DOSIFICACIoN ORAL SoLIDA FORMADA A PARTIR DE DICHA COMPOSICIoN Y PROCEDIMIENTO PARA PRODUCIR DICHA COMPOSICIoN | |
| UY28509A1 (es) | Formas de dosificacion de azitromicina con efectos secundarios reducidos | |
| SV2002000342A (es) | Inhibidor de la glucogeno fosforilasa ref. pc.10753/20151/bb | |
| DE60125825D1 (de) | Parfümzusammensetzungen | |
| CL2004002017A1 (es) | Forma de dosificacion termoformada a prueba de abuso que contiene (a) uno o mas principios activos susceptibles de abuso, (b) opcionalmente sustancias auxiliares, (c) al menos un polimero sintetico o natural de un grupo definido y (d) opcionalmente a | |
| AR018109A1 (es) | FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA | |
| NO20025621D0 (no) | Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser | |
| AR036745A1 (es) | Producto en forma de gel liquido de alta eficacia | |
| BR0215193A (pt) | Formulações de azitromicina diretamente compressìveis | |
| BRPI0519212A2 (pt) | composiÇÕes farmacÊuticas de desintegraÇço oral contendo agentes de manifestaÇço sensorial | |
| GEP20063882B (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| ECSP034826A (es) | Método para fabricar una composición farmacéutica de dosis baja | |
| JP2003508328A5 (enExample) | ||
| ATE499939T1 (de) | Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend | |
| GT200600023A (es) | Combinacion de xolair con agente inmunosupresivo | |
| GT200000141A (es) | Material cementoso extruible. | |
| BR0111868A (pt) | Composições farmacêuticas | |
| UY27727A1 (es) | Nueva composicion farmacéutica- | |
| BR0314787A (pt) | Forma de dosagem de liberação modificada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |